Table 1. Participants in the NIH AMP consortium. The NIH has formed a public-private partnership, called the Accelerating Medicines Partnership (AMP), with industry and not-for-profit organizations to accelerate discovery of targets and biomarkers in Alzheimer's disease (AD), type 2 diabetes, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The not-for-profit Foundation for the National Institutes of Health will manage the funds and operations.

Government

Industry

Not-for-profit organizations

FDA

AbbVie Inc. (NYSE:ABBV)

Alzheimer's Association

NIH Office of the Director

Biogen Idec Inc. (NASDAQ:BIIB)

American Diabetes Association

National Institute on Aging

Bristol-Myers Squibb Co. (NYSE:BMY)

Foundation for the National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

Geoffrey Beene Foundation Alzheimer's Initiative

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Johnson & Johnson (NYSE:JNJ)

Lupus Foundation of America Inc.

National Institute of Allergy and Infectious Diseases

Eli Lilly and Co. (NYSE:LLY)

Pharmaceutical Research and Manufacturers of America

 

Merck & Co. Inc. (NYSE:MRK)

Rheumatology Research Foundation

 

Pfizer Inc. (NYSE:PFE)

USAgainstAlzheimer's

 

Sanofi (Euronext:SAN; NYSE:SNY)

 

 

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)